Henry Gosebruch has been appointed founding chief executive of a new company created by Galapagos NV to focus on drug discovery. The new company is being capitalised with €2.45 billion from Galapagos to investigate new medicines in oncology, immunology and/or virology. Mr Gosebruch was most recently CEO of Neumora Therapeutics Inc, a US-based neuroscience drug developer. Separately Galapagos, the parent company, will continue to build a cell therapy portfolio under the leadership of Paul Stoffels. Dr Stoffels has announced plans to retire as CEO but continue as chair of the board of directors.
Galapagos announced the appointment on 21 April 2025.
Copyright 2025 Evernow Publishing Ltd